Goki Ishikawa named to TIME’S 2026 TIME100 Health List of the World’s Most Influential Leaders in Health
The 2026 TIME100 Health spotlights the 100 most influential leaders in health this year. As the global order has shifted, these titans, innovators, leaders, pioneers, and catalysts have pushed new ideas—from gene therapies to regulatory agencies—ahead to build healthier populations around the world. Goki Ishikawa is recognized in the “Pioneers” category for advancing the development of a blood-based test that is less invasive than previous tests, thereby expanding the potential for earlier diagnosis and treatment of Alzheimer’s disease[1].
Under his leadership, Fujirebio received the first clearance from the U.S. Food and Drug Administration (FDA) in May 2025 for a blood-based in vitro diagnostic test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline[2], and subsequently filed the test for manufacturing and marketing approval with the Ministry of Health, Labour and Welfare in Japan[3].
As part of its important global strategy, the H.U. Group will further contribute to advancing diagnosis and treatment in the field of neurological diseases, including Alzheimer’s disease.
- For more details, see TIME’s special website (TIME100 Most Influential People in Health 2026 | TIME): TIME100 Most Influential People in Health 2026 | TIME
- Press release dated May 16, 2025 “Fujirebio receives marketing clearance for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test as an aid to identify patients with amyloid pathology associated with Alzheimer's disease”
- Press release dated November 25, 2025 “Application for Manufacturing and Marketing Authorization in Japan for Blood-Based IVD Test to Aid in Identifying Amyloid Pathology Associated with Alzheimer's Disease”
Contacts:
For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
Email: pr@hugp.com
For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926
Email: ir@hugp.com
